Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cardiovascular disease

Hyperlipidemia

Angiopoietin-like 8
(ANGPTL8); ANGPTL3

In vitro and mouse studies suggest inhibiting activation of ANGPTL8 or ANGPTL3 could help treat hyperlipidemia. Cleavage of ANGPTL3 activates the protein and is necessary for ANGPTL3-mediated inhibition of lipases, which break down lipids. In cultured hepatocytes, coexpression of ANGPTL3 and ANGPTL8 led to cleavage of ANGPTL3, whereas expression of ANGPTL3 alone did not. In mice with liver-specific overexpression of Angptl8, knocking out Angptl3 led to lower hyperlipidemia than that in wild-type controls. Next steps could include identifying ANGPTL8 inhibitors.

SciBX 5(47); doi:10.1038/scibx.2012.1234
Published online Dec. 6, 2012

Patent and licensing status unavailable

Quagliarini, F. et al. Proc. Natl. Acad. Sci. USA; published online Nov. 12, 2012;
doi:10.1073/pnas.1217552109
Contact: Helen H. Hobbs, The University of Texas Southwestern Medical Center, Dallas, Texas
e-mail:

helen.hobbs@utsouthwestern.edu
Contact: Jonathan C. Cohen, same affiliation as above
e-mail:

jonathan.cohen@utsouthwestern.edu